Versant Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.45K Hold
61
– – ﹤0.01% 2657
2026
Q2
$1.48K Buy
+61
New +$1.04K ﹤0.01% 2598

Other funds holding NRIX

Versant Capital Management's NRIX Position: Q3 2026 in Review

Versant Capital Management held its Nurix Therapeutics (NRIX) position steady in Q3 2026 at 61 shares worth $1.45K. The position accounts for ﹤0.01% of the portfolio, ranked #2657.

Versant Capital Management first reported a position in NRIX in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.48K in Q2 2026. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Versant Capital Management held 61 shares of Nurix Therapeutics worth $1.45K as of Q3 2026.
  • Versant Capital Management left its Nurix Therapeutics share count unchanged in Q3 2026.
  • Nurix Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2657 holding.
  • Versant Capital Management first reported a position in Nurix Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Versant Capital Management's Nurix Therapeutics position peaked at $1.48K in Q2 2026.
  • 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.